跳至主要内容
临床试验/NCT02701374
NCT02701374已完成2 期

TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia -Double Blind Comparison With Placebo-

Toray Industries, Inc1 个研究点 分布在 1 个国家目标入组 184 人开始时间: 2016年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
184
试验地点
1
主要终点
Change in average Numerical Rating Scale (NRS)

研究概览

简要总结

In Post-Herpetic Neuralgia(PHN) patients:

  • To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study
  • To measure the plasma concentration of TRK-700 and its metabolites

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
20 Years 至 84 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with pain persisting for at least 3 months after the onset of herpes zoster
  • Patients whose average pain score on the Numerical Rating Scale (NRS) over the past 24 hours at preliminary enrollment is at least 4

排除标准

  • Patients with another skin disease that may affect the evaluation of the pain at the site of PHN
  • Patients with pain other than PHN that may affect the evaluation of pain
  • Patients with pain that is suspected to be mainly psychogenic
  • Patients who have received neurolytic or neurosurgical therapy for PHN

研究组 & 干预措施

1:TRK-700

Experimental

high dose

干预措施: TRK-700 (Drug)

2:TRK-700

Experimental

low dose

干预措施: TRK-700 (Drug)

3:Placebo

Placebo Comparator

Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Change in average Numerical Rating Scale (NRS)

时间窗: baseline to week 8

Change in average NRS collected by Pain Diary from baseline to week 8 in subjects receiving TRK-700 versus Placebo

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验